Redifferentiation of Iodine-Refractory BRAF V600e-Mutant Metastatic Papillary Thyroid Cancer With Dabrafenib

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-2915
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Newly Diagnosed Papillary Craniopharyngioma With BRAF V600E Mutation Treated With Single-Agent Selective BRAF Inhibitor Dabrafenib: A Case Report

Oncotarget
Oncology
2019English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

The BRAF V600E Mutation Is a Predictor of the Effect of Radioiodine Therapy in Papillary Thyroid Cancer

Journal of Cancer
Oncology
2020English

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression

Clinical Cancer Research
Cancer ResearchOncology
2016English

Targeted Treatment of Papillary Craniopharyngiomas Harboring BRAF V600E Mutations

Cancer
Cancer ResearchOncology
2019English

Prognostic Utility of BRAF Mutation in Papillary Thyroid Cancer

Molecular and Cellular Endocrinology
BiochemistryEndocrinologyMolecular Biology
2010English

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients With Acromegaly

PLoS ONE
Multidisciplinary
2014English

Granulomatosis With Polyangiitis in a Patient Treated With Dabrafenib and Trametinib for BRAF V600E Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy